You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.14)︱京東數科9月10日向上交所提交上市申請;三生製藥貝伐珠單抗生物類似藥中國IND獲受理
格隆匯 09-14 23:02

【新股上市】

京東(09618.HK):京東數科向上交所提交上市申請

威高股份(01066.HK)擬分拆血管及癌症介入手術一次性醫療器械業務並獨立上市

【財務數據】

ISP GLOBAL(08487.HK)年度純利增長180%至28.4萬坡元

新昌創展控股(01781.HK)中期由盈轉虧1814.6萬港元

浙江聯合投資(08366.HK)首財季淨虧約130萬港元

泰錦控股(08321.HK)首季盈轉虧至125.5萬港元

【業績預告】

NOMAD TECH(08645.HK)預計年度由盈轉虧60萬令吉

【運營數據】

中國中冶(01618.HK)前8月新籤合同額6003.4億元 同比增長27.0%

中國南方航空股份(01055.HK)8月旅客週轉量同比下降44.03% 客座率為73.19%

眾安在線(06060.HK)前8月原保費收入96.03億元 同比增長11.39%

佳源國際控股(02768.HK)8月合同銷售額升22%至30.562億元

萊爾斯丹(00738.HK)二季度自營零售業務銷售同比下跌23.7%

【增減持】

華油能源(01251.HK)獲執行董事兼行政總裁再次增持200萬股

【併購出售】

卜蜂國際(00043.HK):正大投資擬281.40億元收購中國豬業務資產

中遠海運港口(01199.HK)附屬擬認購北集司26%股權

火巖控股(01909.HK)擬收購深圳一家網絡遊戲營運服務營運商

達力普控股(01921.HK)擬1140萬元收購盛捷石油管餘下1%股權

【重大事項】

三生製藥(01530.HK):貝伐珠單抗生物類似藥IND申請於中國大陸獲受理

上海醫藥(02607.HK):鹽酸克林黴素膠囊通過仿製藥一致性評價

亞盛醫藥-B(06855.HK):胃癌治療藥APG-115獲美國FDA孤兒藥資格認定

中國生物製藥(01177.HK):降糖藥"沙格列汀片"獲批上市

冠華國際控股(00539.HK)成立合營以共同營運針織布料產品銷售及製造

澳能建設(01183.HK)攜手Ubitricity於大灣區開展電動汽車充電項目合作

【每股資產】

首都創投(02324.HK)8月末每股綜合資產淨值約1.7595港元

【回購註銷】

創維集團(00751.HK)完成股份回購要約 黃氏一致行動集團持股增至46.90%

上海電氣(02727.HK)9月14日耗資1047.17萬港元回購455萬股

英皇娛樂酒店(00296.HK)9月14日耗資113.76萬港元回購96萬股

中國水務(00855.HK)9月14日耗資109.23萬港元回購18.2萬股

石四藥集團(02005.HK)9月14日耗資232.6萬港元回購50萬股

復星國際(00656.HK)9月14日耗資422.84萬港元回購50萬股

DYNAM JAPAN(06889.HK)9月14日耗資44.41萬港元回購5.6萬股

康臣藥業(01681.HK)9月14日耗資171.4萬港元回購48.3萬股

【股權激勵】

綠城服務(02869.HK)授出合計2577萬份購股權

友誼時光(06820.HK):採納股份獎勵計劃

友誼時光(06820.HK):控股股東擬無償贈予8000萬股作為獎勵計劃的股份儲備

【債務融資】

華人策略控股(08089.HK)擬發行1.98億港元換股債 兑換價折讓14.1%

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account